

SERBIA TRANSPARENCY REPORT - Angelini Pharma

Date of publication 28/06/2021

	Full name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier OPTIONAL <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	MARIC NADJA	BELGRADE	SERBIA	Palmoćićeva 37	-	N/A	N/A	-	-	3.500,00 €	-	3.500,00 €
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A	-	-	-	-	-
Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A	-	-	-	-	-
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - Art. 3.02						N/A	N/A	-	-	-	-	-
HCOs												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	-	-	-	-	-	-	-	-	-	-	-	-
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						-	-	-	-	-	-	-
Number of Recipients in aggregate disclosure - Art. 3.02						-	-	-	-	-	-	-
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - Art. 3.02						-	-	-	-	-	-	-
R&D												
<i>AGGREGATE DISCLOSURE</i>												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											-	-